Summary of Significant Accounting Policies (Tables)
|
12 Months Ended |
Dec. 31, 2022 |
Accounting Policies [Abstract] |
|
Disaggregation of revenue |
Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. | | | | | | | | | | | | | | | | | | In thousands of US dollars ($) | Year Ended December 31, 2022 | Products By Geographic Area | Total | | U.S. | | Rest of World | Drug Revenues | | | | | | Product Sales - Point-in-time | $ | 903 | | | $ | 561 | | | $ | 342 | | License Fee – Over time | 256 | | | — | | | 256 | | Total Drug Products | 1,159 | | | 561 | | | 598 | | Concentrate Products | | | | | | Product Sales – Point-in-time | 69,162 | | | 62,715 | | | 6,447 | | License Fee – Over time | 2,489 | | | 2,489 | | | — | | Total Concentrate Products | 71,651 | | | 65,204 | | | 6,447 | | Net Revenue | $ | 72,810 | | | $ | 65,765 | | | $ | 7,045 | | | | | | | | In thousands of US dollars ($) | Year Ended December 31, 2021 | Products By Geographic Area | Total | | U.S. | | Rest of World | Drug Revenues | | | | | | Product Sales - Point-in-time | $ | 835 | | | $ | 835 | | | $ | — | | License Fee – Over time | 241 | | | — | | | 241 | | Total Drug Products | 1,076 | | | $ | 835 | | | 241 | | Concentrate Products | | | | | | Product Sales – Point-in-time | 58,913 | | | 52,614 | | | 6,299 | | License Fee – Over time | 1,942 | | | 1,942 | | | — | | Total Concentrate Products | 60,855 | | | 54,556 | | | 6,299 | | Net Revenue | $ | 61,931 | | | $ | 55,391 | | | $ | 6,540 | |
|
Contract balances |
The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers. | | | | | | | | | | | | In thousands of US dollars ($) | December 31, 2022 | | December 31, 2021 | Receivables, which are included in "Trade and other receivables" | $ | 6,259 | | | $ | 5,913 | | Contract liabilities | $ | 4,331 | | | $ | 8,157 | |
|
Summary of potentially dilutive securities |
Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the years ended December 31, 2022 and 2021 were as follows: | | | | | | | | | | | | | As of December 31, | | 2022 | | 2021 | Options to purchase common stock | 1,206,905 | | | 528,591 | | Unvested restricted stock awards | 891 | | | 7,118 | | Unvested restricted stock units | 125,000 | | | 29,289 | | Convertible Preferred Stock | 1,363,636 | | | — | | Common stock issuable under pre-funded warrants | 6,300,000 | | | — | | Warrants to purchase common stock | 10,196,268 | | | 2,402,442 | | Total | 19,192,700 | | | 2,967,440 | |
|